Both finasteride and dutasteride belong to the same drug class — 5-alpha reductase inhibitors — and both work by reducing DHT. The difference is in how much DHT they block and which enzyme isoforms they target. This comparison lays out the clinical evidence, the practical tradeoffs, and who each drug is actually appropriate for.
Quick Answer
Dutasteride is the stronger DHT blocker with modestly superior hair counts in head-to-head trials. But finasteride is FDA-approved, better studied for hair loss specifically, and has faster washout if side effects occur. Start with finasteride; consider dutasteride if results are insufficient.
How They Work: The Mechanism Difference
Both drugs block 5-alpha reductase (5-AR) — the enzyme that converts testosterone to dihydrotestosterone (DHT). DHT is the androgen primarily responsible for follicle miniaturization in androgenetic alopecia.
The key difference is which isoforms of 5-AR each drug blocks:
Finasteride inhibits type II 5-alpha reductase only — the isoform found primarily in hair follicle dermal papilla cells. This reduces serum DHT by approximately 60-70% and scalp DHT by roughly 60-65%.
Dutasteride inhibits both type I and type II 5-alpha reductase. Type I is found in sebaceous glands and the scalp epidermis, contributing a portion of scalp DHT production. Blocking both isoforms reduces serum DHT by approximately 90-95% — roughly 30% more suppression than finasteride.
The theory: more complete DHT suppression means more preserved follicles and potentially more regrowth. The clinical evidence supports this in head-to-head trials, though the effect size is moderate rather than dramatic.
Head-to-Head Evidence
| Finasteride 1mg | Dutasteride 0.5mg | |
|---|---|---|
| FDA-approved for hair loss | Yes (US, EU, UK) | No (off-label in US/EU; approved in South Korea, Japan) |
| Isoforms blocked | Type II only | Type I + Type II |
| DHT reduction (serum) | ~60-70% | ~90-95% |
| Half-life | ~6 hours | ~5 weeks |
| Evidence base (hair loss) | Extensive (25+ years) | Solid but smaller |
| Hair count advantage vs. other | Established standard | Modest-to-moderate advantage |
| Side effect onset | Similar to dutasteride | Similar to finasteride |
| Side effect resolution if stopped | Rapid (days to weeks) | Slow (weeks to months) |
The 2006 Phase II Trial
A pivotal phase II trial randomized 416 men to dutasteride (0.05, 0.1, 0.5, or 2.5mg), finasteride 5mg, or placebo for 24 weeks. Dutasteride increased target area hair count versus placebo in a dose-dependent fashion, and dutasteride 2.5mg was superior to finasteride 5mg at 12 and 24 weeks.
The 2014 Randomized Trial
A randomized, placebo-controlled trial published in the Journal of the American Academy of Dermatology enrolled 917 men and compared dutasteride (0.02, 0.1, or 0.5mg) with finasteride 1mg and placebo over 24 weeks. Dutasteride 0.5mg showed statistically superior improvement over finasteride 1mg:
- Hair count and hair width: significantly greater increases with dutasteride 0.5mg
- Panel photographic assessment (frontal view) also favored dutasteride
- A 2022 network meta-analysis estimated dutasteride 0.5mg's advantage over finasteride 1mg at about 7 hairs/cm² at 24 weeks
A 2016 open-label Japanese study (no finasteride comparison group) found dutasteride 0.5mg improved hair counts from baseline over 52 weeks and was generally well tolerated.
What the Evidence Actually Tells Us
Dutasteride is genuinely more effective on hair count measures in controlled trials. The difference is real but moderate — not a quantum leap. Clinically, this translates to somewhat better hair density and global appearance, but both drugs preserve hair and some men regrow.
The caveat: most comparative data is at 24-52 weeks. Long-term data (5+ years) comparing the two specifically for hair loss is limited. Finasteride has decades of real-world data; much of dutasteride's hair loss data comes from trials and clinical use in Asia, including South Korea and Japan, where it is approved.
Side Effects: Similar Profile, Different Timeline
The side effects of both drugs are qualitatively identical — same class, same mechanism, same category of effects.
Sexual Side Effects
Both drugs can cause decreased libido, erectile dysfunction, and decreased ejaculate volume. In BPH trials of dutasteride 0.5mg — the same dose used off-label for hair loss — impotence was reported by 4.7% of men and decreased libido by 3.0% in the first 6 months (vs. 1.7% and 1.4% on placebo). In the finasteride 1mg hair loss trials, 3.8% of men reported any sexual side effect (vs. 2.1% on placebo). The BPH trials enrolled older men, so the numbers aren't directly comparable; a 2019 meta-analysis of hair loss trials found a statistically significant increase in sexual dysfunction for finasteride but not for dutasteride, though dutasteride data were limited.
The Critical Difference: Half-Life
This is the most practically important distinction for most men considering dutasteride.
Finasteride half-life: ~6 hours. If you experience a side effect and stop, the drug is substantially cleared within 24-48 hours. DHT levels return to normal within days to weeks. Any side effects typically begin resolving quickly.
Dutasteride half-life: ~5 weeks. If you experience a side effect and stop, the drug is still circulating for weeks. DHT suppression persists for months after the last dose. Side effects that occur may take significantly longer to resolve.
For a treatment primarily used for a cosmetic indication (hair loss, not a life-threatening condition), this difference matters. Men with lower risk tolerance for potential side effects should weigh this carefully. The longer the half-life, the longer you're committed to the drug's effects after stopping.
Post-Treatment Concerns
The post-finasteride syndrome literature is larger than any comparable dutasteride literature — partly because finasteride has been used for hair loss much longer and more widely. This does not necessarily mean dutasteride is safer for long-term use; it may simply reflect the smaller user base for this indication.
Who Is Each Drug For?
Start with finasteride if:
- You are treatment-naive
- You want the FDA-approved, extensively studied standard of care
- You prefer faster washout as a risk management consideration
- You want to establish a baseline of response before escalating
Consider dutasteride if:
- You tried finasteride for 12-18 months and had partial but insufficient response
- You want the most aggressive DHT suppression available
- You are comfortable with the off-label status and understand the longer half-life implications
- You are working with a dermatologist who can evaluate your individual case
Avoid dutasteride if:
- You are trying to conceive — dutasteride measurably reduces semen parameters at 0.5mg and the effect persists for months after stopping
- You have low tolerance for the idea of a medication that stays in your system for weeks after stopping
- You have not yet tried finasteride — there is no good argument to skip the FDA-approved first-line option
Cost and Access
Finasteride: Generic finasteride 1mg is available via telehealth from Keeps, Hims, and Ro. GoodRx at retail pharmacies can bring it below $20/mo.
Dutasteride: Generic dutasteride 0.5mg (generic Avodart) runs approximately $15-40/mo at retail with a prescription. Several telehealth platforms prescribe it off-label for hair loss — RXSpan MD LegitScript Certified is one of the few that offers dutasteride online (choose the hair-loss treatment once you're on their site), and Ro and Happy Head prescribe it too. Cost is often competitive with finasteride.
Our Verdict
For most men starting treatment, finasteride 1mg is the right first choice. It is FDA-approved, backed by 25+ years of evidence specifically for hair loss, and has faster washout if any side effects occur.
If finasteride produces partial but insufficient results after 12-18 months of consistent use, dutasteride is a clinically reasonable step-up option. The superior DHT suppression translates to modestly better hair counts in controlled trials, and the side effect profile is qualitatively similar — the main consideration is the longer half-life.
Discuss the switch with a dermatologist rather than making it unilaterally. Individual responses to both drugs vary, and a clinician can assess whether a step-up is appropriate for your specific pattern and response.
For the full breakdown of finasteride, see our complete finasteride guide. For the full dutasteride overview, see our dutasteride treatment guide.
Sources
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. Journal of the American Academy of Dermatology. 2006;55(6):1014-1023. PMID: 17110217.
- Jung JY, Yeon JH, Choi JW, et al. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. International Journal of Dermatology. 2014;53(11):1351-1357. PMID: 24898559.
- Tsunemi Y, Irisawa R, Yoshiie H, et al. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. Journal of Dermatology. 2016;43(9):1051-1058. PMID: 26893187.
- Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. Journal of the American Academy of Dermatology. 1998;39(4):578-589. PMID: 9777765.
- Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. Journal of the American Academy of Dermatology. 2017;77(1):136-141. PMID: 28396101.
- Gubelin Harcha W, Barboza Martínez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. Journal of the American Academy of Dermatology. 2014;70(3):489-498. PMID: 24411083.
- Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Relative efficacy of minoxidil and the 5-alpha reductase inhibitors in androgenetic alopecia treatment of male patients: a network meta-analysis. JAMA Dermatology. 2022;158(3):266-274. PMID: 35107565.
- Lee S, Lee YB, Choe SJ, Lee WS. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. Acta Dermato-Venereologica. 2019;99(1):12-17. PMID: 30206635.
- Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. Journal of the American Academy of Dermatology. 1999;41(4):550-554. PMID: 10495374.
- U.S. Food and Drug Administration. Avodart (dutasteride) prescribing information; revised 2023. DailyMed.